The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
There are a growing number of investigations of novel combination therapies for chronic lymphocytic leukemia (CLL). These are discussed in this interview with Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, which took place at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Prof. Hillmen provides an insight into the novel agents currently in trials, as well as the pros and cons of ibrutinib, and how it stacks up against a next-generation BTK inhibitor combination that is more specific, tolerable and has shown fewer side effects for CLL patients.
